Bristol-Myers Squibb Fights Immuno-oncology Competition with Early stage Biotech Acquisition
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 8 (Table of Contents)
Published: 19 Aug-2017
DOI: 10.3833/pdr.v2017.i8.2266 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Building its immuno-oncology pipeline, Bristol-Myers Squibb (BMS) has agreed to acquire start-up biotech, IFM Therapeutics, in a deal worth up to US$2...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS